한글목차

피부과 처방약시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 400억 달러에서 2026년에는 425억 4,000만 달러에 이르고, CAGR 6.3%로 성장할 전망입니다. 지난 몇 년간의 성장에는 여드름과 피부염의 높은 발병률, 외용 코르티코스테로이드의 광범위한 사용, 피부과 클리닉의 확대, 피부 감염 사례 증가, 의사의 처방률 증가 등이 요인으로 작용한 것으로 추정됩니다.

처방 피부과용 의약품 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 542억 7,000만 달러에 이르고, CAGR은 6.3%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 건선 유병률 증가, 첨단 피부과용 의약품에 대한 수요 증가, 고령화에 따른 피부질환 증가, 전문 피부과 의료 확대, 피부 건강에 대한 인식 개선 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 만성 피부질환 유병률 증가, 처방전 수준의 외용제 수요 증가, 복합 피부치료법 보급 확대, 장기 피부질환 관리 확대, 표적형 피부질환 치료제 도입 증가 등을 꼽을 수 있습니다.

피부 관련 질환의 발생률 증가는 처방용 피부과 의약품 시장의 확대를 촉진할 것으로 예측됩니다. 습진, 건선, 여드름, 곰팡이 감염 등 피부, 모발, 손톱에 영향을 미치는 질환으로 치료가 필요한 경우가 많습니다. 그 증가 요인은 도시화, 오염, 생활방식의 변화로 인한 유발 요인에 대한 노출 증가에 있습니다. 시장에서는 증상 억제, 발병 완화, 환자의 건강 증진을 위한 전문적인 치료를 제공함으로써 이 문제에 대응하고 있습니다. 예를 들어, 2023년 10월 유럽피부과학회(EADV)가 유럽 27개국 성인 44,689명을 대상으로 실시한 설문조사에 따르면, 응답자의 43%가 지난 1년간 최소 한 가지 이상의 피부질환을 경험했으며, 곰팡이 감염, 습진(아토피 피부염), 탈모증, 여드름이 가장 빈번한 질환인 것으로 나타났습니다. 것으로 나타났습니다. 이처럼 피부질환의 급증은 처방용 피부약 시장의 성장을 견인하고 있습니다.

처방용 피부과 의약품 시장의 주요 기업들은 결절성 소양증에 대한 새로운 치료제 개발을 우선적으로 추진하고 있으며, 인터루킨-31(IL-31) 수용체 길항제 등을 통해 환자들에게 우수한 질환 관리와 지속적인 증상 완화를 제공합니다. IL-31 수용체 길항제는 결절성 소양증에서 심한 가려움증과 피부 염증의 주요 원인인 IL-31 신호전달 경로를 억제하는 생물학적 제제입니다. 예를 들어, 2024년 12월 스위스에 본사를 둔 피부과 기업 갈더마(Garderma)는 IL-31 수용체 α를 표적으로 하는 완전 인간형 단클론 항체 '네뮬비오(네몰리주맙)'의 미국 FDA 승인을 획득했습니다. 이 치료법은 여러 주요 임상시험에서 가려움증 강도와 결절 수를 유의하게 감소시켜 결절성 소양증 환자들에게 효과적임을 입증했습니다. 네므비오는 4주에 한 번 피하주사로 투여하기 때문에 장기적인 관리와 환자의 복약 순응도를 높일 수 있는 간편한 치료 요법을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Prescription dermatological drugs are medications prescribed by healthcare professionals to address a range of skin conditions. They help manage problems like acne, eczema, psoriasis, and various other skin disorders, typically featuring active ingredients that demand medical oversight.

The primary categories of prescription dermatological medications include corticosteroids, retinoids, calcineurin inhibitors, antifungal agents, antibiotics, and additional types. Corticosteroids, which consist of steroid hormones from the adrenal cortex or their synthetic counterparts, primarily help reduce inflammation and dampen immune activity in various conditions. Doctors often prescribe these for issues like acne, psoriasis, dermatitis, fungal skin infections, and more, with distribution occurring via channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

Tariffs have raised the cost of imported APIs and specialty dermatological formulations used in prescription creams, ointments, and oral therapies. These impacts are most pronounced across hospital and retail pharmacy channels in Asia Pacific and Europe, where dependence on cross border pharmaceutical sourcing remains high. Rising tariff related expenses have placed pressure on manufacturing costs, pricing strategies, and product availability. This has influenced procurement planning and inventory management for dermatology treatments. Positively, tariffs are supporting local dermatological drug manufacturing, expanded formulation development, and stronger regional pharmaceutical supply chains over the long term.

The prescription dermatological drugs market research report is one of a series of new reports from The Business Research Company that provides prescription dermatological drugs market statistics, including prescription dermatological drugs industry global market size, regional shares, competitors with a prescription dermatological drugs market share, detailed prescription dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription dermatological drugs industry. This prescription dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prescription dermatological drugs market size has grown strongly in recent years. It will grow from $40 billion in 2025 to $42.54 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high incidence of acne and dermatitis, widespread use of topical corticosteroids, expansion of dermatology clinics, growth in skin infection cases, increased physician prescribing rates.

The prescription dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $54.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising psoriasis prevalence, increasing demand for advanced dermatology drugs, growth in aging population skin disorders, expansion of specialty dermatology care, increasing awareness of skin health. Major trends in the forecast period include rising prevalence of chronic skin disorders, growing demand for prescription-strength topicals, increasing use of combination dermatology therapies, expansion of long-term skin disease management, increased adoption of targeted dermatological drugs.

The rising incidence of skin-related disorders is anticipated to fuel expansion in the prescription dermatological drugs market. These disorders impact the skin, hair, and nails-such as eczema, psoriasis, acne, and fungal infections-and often demand medical treatment. Their growing occurrence stems from urbanization, pollution, and shifting lifestyles, which heighten exposure to triggers that worsen these issues. The market addresses this by offering specialized treatments that control symptoms, minimize outbreaks, and enhance patients' well-being. For example, in October 2023, a European Academy of Dermatology and Venereology (EADV) survey of 44,689 adults from 27 European countries revealed that 43% had experienced at least one skin condition in the previous year, with fungal infections, eczema (atopic dermatitis), alopecia, and acne being the most frequent. Thus, the surge in dermatological conditions is propelling the prescription dermatological drugs market forward.

Major companies in the prescription dermatological drugs market are prioritizing the development of novel therapies for prurigo nodularis, including interleukin-31 (IL-31) receptor antagonists, to deliver superior disease control and sustained relief for patients. An IL-31 receptor antagonist is a biologic agent that blocks the IL-31 signaling pathway, a key driver of severe itching and skin inflammation in prurigo nodularis. For example, in December 2024, Galderma, a dermatology firm based in Switzerland, secured US FDA approval for Nemluvio (nemolizumab), a fully human monoclonal antibody targeting the IL-31 receptor alpha. The treatment demonstrated significant reductions in itch intensity and nodule count in several key clinical trials, underscoring its efficacy for prurigo nodularis patients. Nemluvio is given via subcutaneous injection once every four weeks, providing a user-friendly regimen that enhances long-term management and patient compliance.

In October 2024, Organon & Co., a U.S.-based pharmaceutical firm, purchased Dermavant Sciences Ltd. for $1.2 billion. Through this deal, Organon seeks to strengthen its dermatology offerings by broadening its lineup of cutting-edge therapies for chronic skin disorders, such as prurigo nodularis and psoriasis. Dermavant Sciences Ltd., a U.S.-based firm, focuses on creating treatments in immunodermatology.

Major companies operating in the prescription dermatological drugs market are Pfizer Inc., Johnson & Johnson, Merck KGaA, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.

North America was the largest region in the prescription dermatological drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription dermatological drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prescription dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prescription dermatological drugs market consists of sales of products such as antifungals, antihistamines, and isotretinoin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prescription Dermatological Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses prescription dermatological drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prescription dermatological drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prescription dermatological drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Corticosteroids; Retinoids; Calcineurin Inhibitors; Antifungal Agents; Antibiotics; Other Drug Classes
• 2) By Indication: Acne; Psoriasis; Dermatitis; Fungal Skin Infections; Other Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
• 2) By Retinoids: Topical Retinoids; Oral Retinoids
• 3) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors; Oral Calcineurin Inhibitors
• 4) By Antifungal Agents: Topical Antifungals; Oral Antifungals
• 5) By Antibiotics: Topical Antibiotics; Oral Antibiotics
• 6) By Other Drug Classes: Immunosuppressants; Phototherapy Agents
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck KGaA; AbbVie Inc.; Bayer AG; Novartis AG; GSK plc; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Inc.; Regeneron Pharmaceuticals Inc.; Mylan NV; Sun Pharmaceutical Industries Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Zydus Cadila Health Care Limited; Leo Pharma A/S; Glenmark Pharmaceuticals Limited; Almirall S.A.; DermBiont Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Prescription Dermatological Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Prescription Dermatological Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Prescription Dermatological Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Prescription Dermatological Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Chronic Skin Disorders
  • 4.2.2 Growing Demand For Prescription-Strength Topicals
  • 4.2.3 Increasing Use Of Combination Dermatology Therapies
  • 4.2.4 Expansion Of Long-Term Skin Disease Management
  • 4.2.5 Increased Adoption Of Targeted Dermatological Drugs

5. Prescription Dermatological Drugs Market Analysis Of End Use Industries

• 5.1 Dermatology Hospitals
• 5.2 Specialty Dermatology Clinics
• 5.3 General Hospitals
• 5.4 Retail Pharmacies
• 5.5 Homecare Patients

6. Prescription Dermatological Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Prescription Dermatological Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Prescription Dermatological Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Prescription Dermatological Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Prescription Dermatological Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Prescription Dermatological Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Prescription Dermatological Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Prescription Dermatological Drugs Market Segmentation

• 9.1. Global Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Corticosteroids, Retinoids, Calcineurin Inhibitors, Antifungal Agents, Antibiotics, Other Drug Classes
• 9.2. Global Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acne, Psoriasis, Dermatitis, Fungal Skin Infections, Other Indications
• 9.3. Global Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
• 9.4. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
• 9.5. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Retinoids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Topical Retinoids, Oral Retinoids
• 9.6. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Topical Calcineurin Inhibitors, Oral Calcineurin Inhibitors
• 9.7. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antifungal Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Topical Antifungals, Oral Antifungals
• 9.8. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Topical Antibiotics, Oral Antibiotics
• 9.9. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunosuppressants, Phototherapy Agents

10. Prescription Dermatological Drugs Market Regional And Country Analysis

• 10.1. Global Prescription Dermatological Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Prescription Dermatological Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Prescription Dermatological Drugs Market

• 11.1. Asia-Pacific Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Prescription Dermatological Drugs Market

• 12.1. China Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Prescription Dermatological Drugs Market

• 13.1. India Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Prescription Dermatological Drugs Market

• 14.1. Japan Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Prescription Dermatological Drugs Market

• 15.1. Australia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Prescription Dermatological Drugs Market

• 16.1. Indonesia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Prescription Dermatological Drugs Market

• 17.1. South Korea Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Prescription Dermatological Drugs Market

• 18.1. Taiwan Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Prescription Dermatological Drugs Market

• 19.1. South East Asia Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Prescription Dermatological Drugs Market

• 20.1. Western Europe Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Prescription Dermatological Drugs Market

• 21.1. UK Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Prescription Dermatological Drugs Market

• 22.1. Germany Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Prescription Dermatological Drugs Market

• 23.1. France Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Prescription Dermatological Drugs Market

• 24.1. Italy Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Prescription Dermatological Drugs Market

• 25.1. Spain Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Prescription Dermatological Drugs Market

• 26.1. Eastern Europe Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Prescription Dermatological Drugs Market

• 27.1. Russia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Prescription Dermatological Drugs Market

• 28.1. North America Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Prescription Dermatological Drugs Market

• 29.1. USA Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Prescription Dermatological Drugs Market

• 30.1. Canada Prescription Dermatological Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Prescription Dermatological Drugs Market

• 31.1. South America Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Prescription Dermatological Drugs Market

• 32.1. Brazil Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Prescription Dermatological Drugs Market

• 33.1. Middle East Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Prescription Dermatological Drugs Market

• 34.1. Africa Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Prescription Dermatological Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Prescription Dermatological Drugs Market Regulatory and Investment Landscape

36. Prescription Dermatological Drugs Market Competitive Landscape And Company Profiles

• 36.1. Prescription Dermatological Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Prescription Dermatological Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Prescription Dermatological Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Prescription Dermatological Drugs Market Other Major And Innovative Companies

• Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.

38. Global Prescription Dermatological Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Prescription Dermatological Drugs Market

40. Prescription Dermatological Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Prescription Dermatological Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Prescription Dermatological Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Prescription Dermatological Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer